In 2012, the three organizations have partnered to combine Novavax’s vaccine technology, ICGEB’s malaria vaccine research expertise and CPLB manufacturing capability.
India’s Department of Biotechnology Vaccine Grand Challenge Program is funding the project while the Malaria Vaccine Development Program is managing the project.
Novavax president and CEO Stanley Erck said, "Malaria remains a major public health problem in many parts of the tropical world and we are committed to identifying a safe and effective vaccine that can prevent its spread and devastating effects."